How We Research
Transparency is our priority. Here's exactly how we create evidence-based cannabis education content—and why you can trust our information.
Our Research Commitment
Citation-first approach: Every therapeutic claim in our content is backed by peer-reviewed research. We don't make claims we can't cite—and you can verify every source yourself via PubMed or DOI links.
What we do: We search PubMed, ClinicalTrials.gov, and authoritative medical databases for relevant studies. Each claim includes a direct link to its source. We clearly label evidence levels (Strong, Moderate, Emerging, Anecdotal) so you know exactly how robust the science is.
What we don't do: We don't make unsubstantiated health claims, cite marketing materials as evidence, or present anecdotes as scientific fact. We don't claim to have medical reviewers we don't have.
Our Research Process
Topic Identification
We identify topics based on patient questions, emerging research, and medical relevance. Topics must have sufficient peer-reviewed literature to support educational content.
Literature Review
We search PubMed, ClinicalTrials.gov, and peer-reviewed journals for relevant studies. We prioritize randomized controlled trials (RCTs), systematic reviews, and meta-analyses.
Evidence Grading
Each claim is assigned an evidence level based on the quality and quantity of supporting research. We're honest when evidence is limited or preliminary.
Citation & Attribution
Every claim links to its source with full bibliographic information, including PubMed IDs and DOIs when available. You can verify any claim yourself.
Medical Review & Regular Updates
Cannabis research evolves rapidly. Our Medical Review Board, led by Dr. Kevin Kargman, DO and Dr. Rajashree Kantha, MD, reviews our content when significant new research emerges. Every page shows its last update date.
Evidence Standards
We categorize evidence by the type and quality of research supporting each claim:
Multiple peer-reviewed clinical trials in humans support this effect. This is our highest confidence level.
Examples: CBD for epilepsy, THC for chemotherapy nausea
Supported by preclinical studies and limited clinical data. Promising but not yet definitively proven in humans.
Examples: CBD for anxiety, myrcene for relaxation
Early research shows promise, but more studies are needed. We note the limitations.
Examples: CBG for IBD, THCV for appetite
Based on user reports and traditional use. Limited or no controlled studies. We're explicit when evidence is anecdotal.
Examples: Specific strain effects, "indica vs sativa" effects
Our Sources
What We Cite
- PubMed-indexed peer-reviewed studies
- FDA documents and approvals
- ClinicalTrials.gov registered trials
- Cochrane systematic reviews
- State health department resources
What We Don't Cite
- Marketing materials from cannabis companies
- Non-peer-reviewed blogs or articles
- Social media claims or influencer content
- Predatory or pay-to-publish journals
- Unverified user testimonials
Our Citation Library
Our educational content currently cites 86 peer-reviewed studies and authoritative sources across the following research areas:
Complete Citation List
Every peer-reviewed study and authoritative source we cite across our educational content. Click any citation to view the original study.
CBD Research (12)
Silvestro S, et al. Therapeutic potential of cannabidiol (CBD) Journal of Cellular Physiology. 2020
Comprehensive review of CBD's therapeutic applications.
Devinsky O, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome New England Journal of Medicine. 2018
Phase III trial leading to FDA approval of Epidiolex.
Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in Dravet Syndrome New England Journal of Medicine. 2017
Pivotal Dravet syndrome trial supporting FDA approval.
Devinsky O, et al. Cannabidiol for treatment-resistant epilepsy Lancet Neurology. 2016
Open-label trial showing 36.5% reduction in seizures.
Shannon S, et al. Cannabidiol in anxiety and sleep: A large case series Permanente Journal. 2019
79.2% of patients reported reduced anxiety within first month.
Bergamaschi MM, et al. CBD reduces anxiety in social anxiety disorder Neuropsychopharmacology. 2011
CBD reduced anxiety in simulated public speaking test.
Burstein S. Cannabidiol as an emergent therapeutic strategy for reducing inflammation Bioorganic & Medicinal Chemistry. 2015
Review of CBD's anti-inflammatory mechanisms.
Shannon S, et al. Cannabidiol for treatment of insomnia Permanente Journal. 2019
66.7% of patients reported improved sleep.
Boyaji S, et al. Cannabidiol for chronic pain management Current Opinion in Anesthesiology. 2020
Review of CBD's analgesic mechanisms.
Casey SL, et al. CBD for neuropathic pain: A systematic review Pain Medicine. 2018
Systematic review of CBD for neuropathic pain.
De Filippis D, et al. CBD reduces intestinal inflammation through CB2 receptors PLOS ONE. 2011
Shows CBD reduces gut inflammation in IBD models.
FDA. FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana FDA News Release. 2018
FDA approval of Epidiolex (CBD) for Dravet and Lennox-Gastaut syndromes.
THC Research (11)
Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish Journal of the American Chemical Society. 1964. doi:10.1021/ja01062a046
Landmark paper first identifying and synthesizing THC.
Whiting PF, et al. Cannabinoids for medical use: A systematic review and meta-analysis JAMA. 2015
Comprehensive review finding moderate evidence for chronic pain.
Aviram J, Samuelly-Leichtag G. Cannabinoids for neuropathic pain Journal of Pain Research. 2017
Review of clinical trials for neuropathic pain.
Lutge EE, et al. Dronabinol for AIDS-related anorexia Cochrane Database of Systematic Reviews. 2013
Systematic review of appetite stimulation evidence.
Smith LA, et al. Cannabinoids for chemotherapy-induced nausea and vomiting Cochrane Database of Systematic Reviews. 2015
High-quality evidence for CINV efficacy.
Kesner AJ, Lovinger DM. Cannabis, cannabinoids, and sleep Neuropsychopharmacology. 2020
Review of THC effects on sleep architecture.
Novotna A, et al. Nabiximols for spasticity in multiple sclerosis European Journal of Neurology. 2011
Phase III trial showing efficacy for MS spasticity.
Cuttler C, et al. Short- and Long-Term Effects of Cannabis on Headache and Migraine Journal of Pain. 2020
Found inhaled cannabis reduced self-reported headache severity by nearly 50%.
Jetly R, et al. Cannabinoid effects on PTSD-related nightmares Psychoneuroendocrinology. 2015
Found nabilone (synthetic THC) reduced nightmare frequency in PTSD patients.
Bonn-Miller MO, et al. A systematic review of the effects of CBD:THC ratios Clinical Psychology Review. 2017
Review of how different THC:CBD ratios affect therapeutic outcomes.
Koppel BS, et al. Cannabinoids for spasticity due to MS Neurology. 2014
AAN guideline review on cannabinoids for MS spasticity.
Linalool Research (7)
Linck VM, et al. Anti-anxiety effects of linalool in mice Phytomedicine. 2010
Linalool reduced anxiety without motor impairment.
Harada H, et al. Linalool odor-induced anxiolytic effects via GABA(A) receptors Frontiers in Behavioral Neuroscience. 2018
Showed linalool acts via olfactory system and GABA-A receptors.
Koulivand PH, et al. Lavender and the nervous system: Clinical evidence Evidence-Based Complementary and Alternative Medicine. 2013
Review of linalool-rich lavender for anxiety and mood.
de Almeida RN, et al. Sedative-hypnotic effects of linalool Pharmaceutical Biology. 2009
Linalool increased sleep time without affecting REM sleep.
Peana AT, et al. Anti-inflammatory activity of linalool Phytomedicine. 2002
Linalool reduced edema and inflammation in rat models.
Batista PA, et al. Antinociceptive effects of linalool in mice Journal of Ethnopharmacology. 2008
Linalool showed analgesic effects via multiple mechanisms.
Elisabetsky E, et al. Anticonvulsant effects of linalool Journal of Ethnopharmacology. 1999
Linalool showed anticonvulsant activity in multiple seizure models.
β-Caryophyllene Research (7)
Gertsch J, et al. β-Caryophyllene is a dietary cannabinoid Proceedings of the National Academy of Sciences. 2008
Landmark paper: BCP directly activates CB2 receptors.
Klauke AL, et al. β-Caryophyllene reduces neuropathic pain via CB2 and PPAR-γ European Journal of Pain. 2014
Showed dual mechanism for neuropathic pain relief.
Bahi A, et al. Anxiolytic-like effect of β-caryophyllene Physiology & Behavior. 2014
BCP reduced anxiety via CB2 receptor activation.
Horvath B, et al. Anti-inflammatory effects of β-caryophyllene Free Radical Biology and Medicine. 2012
BCP reduced inflammation markers and oxidative stress.
Tambe Y, et al. Gastroprotective effects of β-caryophyllene Planta Medica. 1996
BCP protected gastric mucosa in ulcer models.
Aguilar-Avila DS, et al. β-Caryophyllene for diabetic neuropathy European Journal of Pharmacology. 2019
BCP reduced neuropathic symptoms in diabetic models.
Bento AF, et al. β-Caryophyllene attenuates colitis via CB2 activation British Journal of Pharmacology. 2011
BCP reduced colitis severity through CB2 receptors.
Other Terpenes (6)
Ito K, Ito M. Sedative properties of terpinolene Journal of Natural Medicines. 2013
Terpinolene prolonged sleep time in mice.
Grassmann J, et al. Antioxidant properties of terpinolene Journal of Agricultural and Food Chemistry. 2001
Terpinolene showed strong antioxidant activity.
Tampieri MP, et al. Antifungal activity of ocimene-rich oils Molecules. 2005
Ocimene showed activity against Candida species.
Gonçalves ECD, et al. Anti-inflammatory properties of ocimene Natural Product Communications. 2018
Ocimene reduced inflammatory markers in vivo.
Quintans-Júnior LJ, et al. Sedative effects of α-terpineol Pharmaceutical Biology. 2011
α-Terpineol showed CNS depressant activity.
Park SN, et al. Antioxidant activity of α-terpineol Korean Journal of Chemical Engineering. 2009
α-Terpineol demonstrated protective antioxidant effects.
CBG Research (5)
Nachnani R, et al. Cannabigerol: A comprehensive review of therapeutic potential ACS Pharmacology & Translational Science. 2021
Most comprehensive CBG review to date.
Borrelli F, et al. Beneficial effect of cannabigerol on experimental inflammatory bowel disease Biochemical Pharmacology. 2013
CBG reduced colitis markers in mouse IBD models.
Valdeolivas S, et al. Neuroprotective properties of cannabigerol in Huntington's disease Neurotherapeutics. 2015
CBG improved motor deficits in HD mouse models.
Appendino G, et al. Antibacterial cannabinoids from Cannabis sativa Journal of Natural Products. 2008
CBG showed potent activity against MRSA.
Colasanti BK. Intraocular pressure-lowering effect of cannabigerol Journal of Ocular Pharmacology. 1990
CBG reduced intraocular pressure in cat models.
Myrcene Research (5)
Surendran S, et al. Myrcene—What Are the Potential Health Benefits of This Flavouring and Aroma Agent? Frontiers in Nutrition. 2021
Comprehensive review: β-myrcene may potentiate the anti-nociceptive properties of cannabinoids.
Sewell RA, et al. The Effects of β-myrcene on Simulated Driving Cannabis and Cannabinoid Research. 2023
Found myrcene alone did not significantly impair simulated driving performance.
do Vale TG, et al. Sedative effects of myrcene in mice Phytomedicine. 2002
Demonstrated dose-dependent sedative and motor-relaxant effects in mice.
Lorenzetti BB, et al. Anti-inflammatory activity of myrcene Journal of Ethnopharmacology. 1991
Found peripheral analgesic activity in animal models.
Rao VS, et al. Antinociceptive action of myrcene Journal of Pharmacy and Pharmacology. 1990
Investigated pain-modulating mechanisms in animal studies.
Entourage Effect & Synergy (4)
Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects British Journal of Pharmacology. 2011
Foundational paper on the entourage effect: how cannabinoids and terpenes work synergistically.
Tagen M, et al. D-Limonene Reduces THC-induced Anxiety via Adenosine A2A Receptor Mechanisms Psychopharmacology. 2024
Johns Hopkins study showing limonene specifically reduces THC-induced anxiety in humans.
Ben-Shabat S, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-AG activity European Journal of Pharmacology. 1998
Original paper proposing the entourage effect concept by Mechoulam's team.
Gallily R, et al. Overcoming the bell-shaped dose-response of CBD by using full-spectrum extract Pharmacology & Pharmacy. 2015. doi:10.4236/pp.2015.62010
Hebrew University study: full-spectrum CBD more effective than isolate at lower doses.
THCA Research (4)
Nallathambi R, et al. THCA anti-inflammatory activity via PPARγ Cannabis and Cannabinoid Research. 2017
THCA activated PPARγ for anti-inflammatory effects.
Nadal X, et al. Neuroprotective effects of THCA British Journal of Pharmacology. 2017
THCA improved motor deficits in HD via PPARγ.
Verhoeckx KC, et al. THCA for arthritis and joint inflammation European Journal of Pharmacology. 2006
Acidic cannabinoids showed COX-2 inhibition.
Rock EM, et al. Tetrahydrocannabinolic acid (THCA) for nausea British Journal of Pharmacology. 2013
THCA reduced nausea more potently than THC in rodent models.
Pinene Research (4)
Lee GY, et al. Alpha-pinene enhances memory via acetylcholinesterase inhibition Dementia and Geriatric Cognitive Disorders. 2017
α-Pinene inhibited AChE and improved memory in mice.
Falk AA, et al. Bronchodilator effects of α-pinene Xenobiotica. 1990
α-Pinene showed bronchodilator activity in humans.
Nam SY, et al. Anti-inflammatory and anti-allergic activities of α-pinene Phytotherapy Research. 2014
α-Pinene reduced IgE-mediated allergic inflammation.
Salehi B, et al. Biological activities of α-pinene: A comprehensive review Biomolecules. 2019
Most comprehensive review of pinene pharmacology.
Humulene Research (4)
Rogerio AP, et al. Anti-inflammatory effects of α-humulene in airways British Journal of Pharmacology. 2009
α-Humulene reduced airway inflammation via NF-κB inhibition.
Satsu H, et al. Gastroprotective effects of α-humulene Molecules. 2020
α-Humulene protected gastric mucosa in multiple models.
Fiorini D, et al. Pharmacological review of α-humulene Phytochemistry Reviews. 2024. doi:10.1007/s11101-024-09876-5
Most recent comprehensive review of humulene pharmacology.
Legault J, Pichette A. Anorexigenic effects of α-humulene Planta Medica. 2007
α-Humulene showed appetite-suppressing properties.
CBN Research (3)
Turner CE, et al. Effects of CBN on sleep in humans Clinical Pharmacology and Therapeutics. 1975
Early human study on CBN's sedative properties.
Farrimond JA, et al. CBN increases food consumption in rats Psychopharmacology. 2012
CBN stimulated appetite and increased meal size.
Appendino G, et al. Antibacterial properties of cannabinoids including CBN Journal of Natural Products. 2008
CBN showed antibacterial activity against resistant bacteria.
CBDA Research (3)
Rock EM, et al. CBDA reduces nausea and vomiting British Journal of Pharmacology. 2013
CBDA 1000x more potent than CBD for 5-HT1A activation.
Takeda S, et al. CBDA selectively inhibits COX-2 Drug Metabolism and Disposition. 2008
CBDA showed selective COX-2 inhibition similar to celecoxib.
Bolognini D, et al. CBDA and 5-HT1A serotonin receptors British Journal of Pharmacology. 2013
Explains CBDA's potent anti-nausea mechanism.
Limonene Research (3)
Vieira AJ, et al. Limonene: Aroma of innovation in health and disease Chemico-Biological Interactions. 2018
Comprehensive review of limonene's anxiolytic and antidepressant effects.
Kiecolt-Glaser JK, et al. Olfactory influences on mood and cognition from citrus fragrance Psychoneuroendocrinology. 2008
Lemon scent exposure improved mood and reduced norepinephrine.
Sun J. D-Limonene for heartburn and GERD Alternative Medicine Review. 2007
D-limonene showed gastroprotective effects.
Neurological Research (3)
Bonn-Miller MO, et al. Cannabis use and PTSD among veterans Journal of Traumatic Stress. 2017
Veterans using cannabis showed PTSD symptom reduction.
Patti F, et al. Long-term efficacy of nabiximols in MS spasticity Journal of Neurology. 2016
Sativex maintained efficacy for MS spasticity over long-term use.
Rice J, Cameron M. Cannabinoids for MS symptom treatment: Systematic review Multiple Sclerosis Journal. 2018
Systematic review supporting cannabinoids for MS symptoms.
Other Cannabinoids (2)
Wargent ET, et al. THCV for obesity and metabolic disorders Nutrition & Diabetes. 2013
THCV improved glucose tolerance and insulin sensitivity in obese mice.
Hill AJ, et al. Anticonvulsant effects of CBDV British Journal of Pharmacology. 2012
CBDV significantly reduced seizure severity in multiple models.
Pain Research (2)
Rhyne DN, et al. Effects of medical marijuana on migraine headache frequency Pharmacotherapy. 2016
Medical marijuana reduced migraine frequency from 10.4 to 4.6 per month.
Russo EB. Clinical endocannabinoid deficiency in migraine Neuroendocrinology Letters. 2008
Proposed clinical endocannabinoid deficiency as migraine mechanism.
Inflammation Research (1)
Naftali T, et al. Cannabis induces clinical response in Crohn's disease Clinical Gastroenterology and Hepatology. 2013
Short-term cannabis produced clinical remission in 45% of Crohn's patients.
How to Verify Our Claims
Every citation in our content links directly to its source. You can verify any claim by:
- Clicking the superscript citation number (e.g., [1]) in any article
- Scrolling to the References section at the bottom of the page
- Clicking the PubMed or DOI link to view the original study
- Reading the study abstract or full text to verify our interpretation
Important: Our content is educational, not medical advice. Always consult a qualified healthcare provider for medical decisions. If you're a medical cannabis patient, our telehealth physicians can provide personalized guidance.
Ready to Learn More?
Explore our evidence-based cannabis education resources, each backed by peer-reviewed research.